Cantargia obtains an “Intention to Grant” notice from the European Patent Office covering the IL1RAP target for the treatment of solid tumors

Cantargia AB (“Cantargia”) hereby announces that the European Patent Office (EPO) has issued an “Intention to Grant communication” for a patent application concerning IL1RAP as a target molecule for antibody therapy and diagnostic methods of several major forms of solid tumors. Cantargia was recently granted a similar patent for leukemia.

Cantargia has obtained information of an Intention to Grant communication from the EPO. The communication concerns the patent application EP2665749 comprising IL1RAP as a target molecule for antibody therapy of solid tumors. The accepted patent claims cover treatment and diagnosis of common tumor forms including e.g. breast cancer, colon cancer, lung cancer and malignant melanoma. In summary, the communication means that the EPO intends to grant a patent following completion of certain administrative requirements. The EPO has already granted Cantargias patent application covering IL1RAP as a target molecule for antibody therapy for leukemia.

“We are very pleased that our IP portfolio is further progressing. In addition to the patent recently granted by EPO in hematological cancers, Cantargia is now securing an even stronger IP for our overall platform comprising four of the major cancer forms that are of significant relevance for further development.” says Göran Forsberg at Cantargia.

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com